EUS-guided Radiofrequency Ablation (EUS-RFA) of Solid Pancreatic Neoplasm Using an 18-gauge Needle Electrode: Feasibility, Safety, and Technical Success

Authors

  • Stefano Francesco Crinò Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, G.B. Rossi University Hospital, Verona
  • Mirko D’Onofrio Department of Radiology, G.B. Rossi University Hospital, Verona
  • Laura Bernardoni Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, G.B. Rossi University Hospital, Verona
  • Luca Frulloni Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, G.B. Rossi University Hospital, Verona
  • Michele Iannelli Department of Radiology, G.B. Rossi University Hospital, Verona
  • Giuseppe Malleo Department of Pancreatic Surgery, The Pancreas Institute, G.B. Rossi University Hospital, Verona
  • Salvatore Paiella Department of Pancreatic Surgery, The Pancreas Institute, G.B. Rossi University Hospital, Verona
  • Alberto Larghi Digestive Endoscopy Unit, Catholic University, Rome, Italy
  • Armando Gabbrielli Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, G.B. Rossi University Hospital, Verona

DOI:

https://doi.org/10.15403/jgld.2014.1121.271.eus

Keywords:

pancreatic ablation, endoscopic ultrasound, pancreatic cancer, pancreatic adenocarcinoma, radiofrequency ablation

Abstract

Background & Aims: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a promising technique for the treatment of pancreatic neoplasm. We evaluated the feasibility, safety, and technical success of pancreatic EUS-RFA performed in a single center.
Methods: 9 consecutive patients (8 with pancreatic adenocarcinoma and 1 with renal cancer metastasis) were referred for EUS-RFA between November 2016 and July 2017. EUS-RFA was performed using 18-gauge internally cooled electrode with a 5 or 10 mm exposed tip. Feasibility, technical success or early and late adverse events were assessed.
Results: One patient was excluded because of a large necrotic portion. EUS-RFA was feasible in all the other 8 (100%) cases. An ablated area inside the tumor was achieved in all treated patients. No early or late major adverse event was observed after a mean follow-up of 6 months. Three patients experienced mild postprocedural abdominal pain.
Conclusions: EUS-RFA seems a feasible, safe, and effective procedure for pancreatic neoplasms. Its role in the treatment and management of pancreatic masses must be further investigated.

March 2018, volume 27, issue 3

Downloads

Published

2018-03-31

How to Cite

1.
Crinò SF, D’Onofrio M, Bernardoni L, Frulloni L, Iannelli M, Malleo G, Paiella S, Larghi A, Gabbrielli A. EUS-guided Radiofrequency Ablation (EUS-RFA) of Solid Pancreatic Neoplasm Using an 18-gauge Needle Electrode: Feasibility, Safety, and Technical Success. JGLD [Internet]. 2018 Mar. 31 [cited 2026 Jun. 10];27(1):67-72. Available from: https://jgld.ro/jgld/index.php/jgld/article/view/127

Issue

Vol. 27 No. 1: March 2018

Section

Original Article